MedTrace Logo

Anti-VEGF Instead of Intraoperative PRP in Proliferative Diabetic Retinopathy

NCT03633266 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2018-08-17

No results posted yet for this study

Summary

To evaluate the efficacy and safety of vitreoretinal surgery combined with anti-VEGF therapy in the replacement of intraoperative PRP in PDR therapy.

Conditions

  • Anti-VEGF
  • Proliferative Diabetic Retinopathy
  • PRP
  • Vitrectomy

Interventions

PROCEDURE

anti-VEGF

vitreoretinal surgery combined with intraoperative anti-VEGF

PROCEDURE

PRP

vitreoretinal surgery combined with intraoperative PRP

Sponsors & Collaborators

  • Wenzhou Medical University

    lead OTHER

Principal Investigators

  • Yong Wei, M.D · The Eye Hospital of Wenzhou Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-01
Primary Completion
2020-12-01
Completion
2022-12-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03633266 on ClinicalTrials.gov